Showing 937 articles by Gus Cairns

Filters Content type: News, About HIV Author: Gus Cairns

Gus joined the editorial team in 2009 and has previously edited HIV Treatment Update and Preventing HIV. He currently focuses on the PrEP in Europe Initiative and on news reporting.

Antibody-based prevention

HIV vaccines and immunotherapies “would be further along” if they had the resources of COVID-19, says leading antibody researcher

News
28 July 2021
The search for a cure

Novel dual antibody therapy partially controls virulent HIV infection in monkeys off treatment

News
23 July 2021
Transgender people

Studies confirm that hormone levels in trans women are not greatly affected by PrEP, or vice versa

News
22 July 2021
PrEP science

PrEP failures in African programmes are rare, but some are happening in people with good adherence

News
21 July 2021
Injectable & long-acting HIV treatment

Twice-a-year injected drug shows promise for first-line HIV treatment

News
19 July 2021
New & experimental HIV treatments

Novel, twice-a-year injected drug suppresses multidrug-resistant HIV in most patients on failing therapy

News
17 July 2021
PrEP

PrEP for women in Europe webinar: Part 2

News
5 July 2021
Undetectable viral load & treatment as prevention

HIV infection may become rare in UK gay men by 2030, researchers say

News
18 June 2021
PrEP

PrEP for women in Europe webinar: Part 1

News
10 June 2021
People & personal stories

Forty years a survivor

News
8 June 2021
Resistance

Injectable HIV therapy should only be given after a check for innate resistance, French study suggests

News
8 June 2021
PrEP science

Users of event-driven PrEP take it when needed, Dutch study finds

News
25 May 2021
Retention & linkage to care

Two times a year is better than four: people spend less time off ART if they only visit their clinic every six months, African study shows

News
17 May 2021
PrEP programmes & uptake

Black Africans in UK have limited knowledge of PrEP despite ongoing risk

News
10 May 2021
PrEP programmes & uptake

Improving on a good start: Scotland examines its first four years of PrEP

News
29 April 2021
PrEP programmes & uptake

England's big PrEP implementation trial releases its enrolment data: young people under-represented

News
23 April 2021
Access to healthcare

Testing homeless people during COVID-19 identifies several new HIV cases, especially in Black people

News
21 April 2021
Injectable & long-acting HIV treatment

Injectable HIV therapy would have to cost less than $131 a year to be cost-effective in Africa

News
16 April 2021
Drug interactions & pharmacokinetics

PrEP does not lower hormone levels in young transgender people, but lower PrEP levels seen in some transgender women

News
16 March 2021
Finance & funding

To be cost-effective, injectable PrEP can only cost about $3000 more than US generic oral PrEP

News
15 March 2021
PrEP science

Interactions between PrEP and gender-affirming hormone therapy A research briefing

About HIV
March 2021
PrEP science

HPTN 083: Injectable PrEP can make breakthrough infections hard to detect

News
10 March 2021
Injectable & long-acting PrEP

Reformulated islatravir implant should provide PrEP for over a year

News
9 March 2021
PrEP

Sex, PrEP and HIV in trans and non-binary people A research briefing

About HIV
March 2021